Rectal Cancer - Pipeline Review, H2 2015


#346361

104pages

Global Markets Direct

$ 2000

In Stock

Rectal Cancer - Pipeline Review, H2 2015

Summary

Global Markets Directs, Rectal Cancer - Pipeline Review, H2 2015, provides an overview of the Rectal Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Rectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rectal Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rectal Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Rectal Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Rectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Rectal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Rectal Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Rectal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Rectal Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Rectal Cancer - Overview 7
Pipeline Products for Rectal Cancer - Comparative Analysis 8
Rectal Cancer - Therapeutics under Development by Companies 9
Rectal Cancer - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Rectal Cancer - Products under Development by Companies 12
Rectal Cancer - Companies Involved in Therapeutics Development 13
AbbVie Inc. 13
Cerulean Pharma, Inc. 14
Hanwha Chemical Corporation 15
Incuron, LLC 16
Karyopharm Therapeutics, Inc. 17
Nanobiotix 18
Peregrine Pharmaceuticals, Inc. 19
Regeneron Pharmaceuticals, Inc. 20
Synta Pharmaceuticals Corp. 21
Rectal Cancer - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
bavituximab - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CRLX-101 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
ganetespib - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
HD-204 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
mepacrine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
NBTXR-3 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
selinexor - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
veliparib - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ziv-aflibercept (recombinant) - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Rectal Cancer - Recent Pipeline Updates 59
Rectal Cancer - Dormant Projects 100
Rectal Cancer - Product Development Milestones 101
Featured News & Press Releases 101
Apr 23, 2014: Abbvie To Present Data On Veliparib At The 2014 American Society Of Clinical Oncology Annual Meeting 101
Nov 10, 2011: Synta Announces Results Show Ganetespib Sensitizes Rectal Cancer Cells To Chemoradiotherapy 101
Appendix 103
Methodology 103
Coverage 103
Secondary Research 103
Primary Research 103
Expert Panel Validation 103
Contact Us 103
Disclaimer 104

List of Tables
Number of Products under Development for Rectal Cancer, H2 2015 7
Number of Products under Development for Rectal Cancer - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Clinical Stage Development, H2 2015 10
Comparative Analysis by Early Stage Development, H2 2015 11
Products under Development by Companies, H2 2015 12
Rectal Cancer - Pipeline by AbbVie Inc., H2 2015 13
Rectal Cancer - Pipeline by Cerulean Pharma, Inc., H2 2015 14
Rectal Cancer - Pipeline by Hanwha Chemical Corporation, H2 2015 15
Rectal Cancer - Pipeline by Incuron, LLC, H2 2015 16
Rectal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 17
Rectal Cancer - Pipeline by Nanobiotix, H2 2015 18
Rectal Cancer - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2015 19
Rectal Cancer - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015 20
Rectal Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2015 21
Assessment by Monotherapy Products, H2 2015 22
Number of Products by Stage and Target, H2 2015 24
Number of Products by Stage and Mechanism of Action, H2 2015 26
Number of Products by Stage and Route of Administration, H2 2015 28
Number of Products by Stage and Molecule Type, H2 2015 30
Rectal Cancer Therapeutics - Recent Pipeline Updates, H2 2015 59
Rectal Cancer - Dormant Projects, H2 2015 100

List of Figures
Number of Products under Development for Rectal Cancer, H2 2015 7
Number of Products under Development for Rectal Cancer - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Clinical Stage Development, H2 2015 10
Assessment by Monotherapy Products, H2 2015 22
Number of Products by Top 10 Targets, H2 2015 23
Number of Products by Stage and Top 10 Targets, H2 2015 23
Number of Products by Top 10 Mechanism of Actions, H2 2015 25
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 25
Number of Products by Top 10 Routes of Administration, H2 2015 27
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 27
Number of Products by Top 10 Molecule Types, H2 2015 29
Number of Products by Stage and Top 10 Molecule Types, H2 2015 29